

Qian Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9195122/publications.pdf>

Version: 2024-02-01

22
papers

868
citations

567281

15
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

1640
citing authors

#	ARTICLE	IF	CITATIONS
1	Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab133.	0.7	24
2	DSTYK Promotes Metastasis and Chemoresistance via EMT in Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 1250.	3.5	17
3	Overexpression of HGF/MET axis along with p53 inhibition induces de novo glioma formation in mice. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa067.	0.7	8
4	<i>Helicobacter pylori</i> -Mediated Immunity and Signaling Transduction in Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 3699.	2.4	45
5	Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight. <i>Journal of Translational Medicine</i> , 2020, 18, 428.	4.4	51
6	Insufficiency of DNA repair enzyme ATM promotes naive CD4 T-cell loss in chronic hepatitis C virus infection. <i>Cell Discovery</i> , 2018, 4, 16.	6.7	40
7	Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 376-386.	5.1	28
8	HCV-associated exosomes promote myeloid-derived suppressor cell expansion via inhibiting miR-124 to regulate T follicular cell differentiation and function. <i>Cell Discovery</i> , 2018, 4, 51.	6.7	34
9	Inhibition of TRF2 accelerates telomere attrition and DNA damage in naïve CD4 T cells during HCV infection. <i>Cell Death and Disease</i> , 2018, 9, 900.	6.3	27
10	Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody. <i>Journal of Translational Medicine</i> , 2018, 16, 253.	4.4	15
11	Met Activation and Carcinogenesis. <i>Current Human Cell Research and Applications</i> , 2018, , 129-154.	0.1	3
12	The HGF/MET Signaling and Therapeutics in Cancer. <i>Current Human Cell Research and Applications</i> , 2018, , 155-181.	0.1	5
13	Near infrared fluorescent imaging of brain tumor with IR780 dye incorporated phospholipid nanoparticles. <i>Journal of Translational Medicine</i> , 2017, 15, 18.	4.4	72
14	Discovery of a highly potent glucocorticoid for asthma treatment. <i>Cell Discovery</i> , 2015, 1, .	6.7	8
15	Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. <i>Journal of Translational Medicine</i> , 2015, 13, 306.	4.4	18
16	Targeting adaptive glioblastoma: an overview of proliferation and invasion. <i>Neuro-Oncology</i> , 2014, 16, 1575-1584.	1.2	206
17	Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. <i>Genes and Cancer</i> , 2013, 4, 247-260.	1.9	35
18	Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 570-575.	7.1	113

#	ARTICLE	IF	CITATIONS
19	RTK inhibition: looking for the right pathways toward a miracle. <i>Future Oncology</i> , 2012, 8, 1397-1400.	2.4	6
20	Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4105-4110.	7.1	20
21	Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2803-2810.	4.1	40
22	A highly invasive human glioblastoma pre-clinical model for testing therapeutics. <i>Journal of Translational Medicine</i> , 2008, 6, 77.	4.4	52